As clinical operations teams become leaner and more cost-constrained, there is a growing demand for more advanced clinical trial analytics tools to better manage fragmented data.
TORONTO (PRWEB)
April 26, 2023
Over the past decade, clinical trial data has become increasingly complex, leading to disconnects between key stakeholders and inefficiencies within drug development. As clinical operations teams become leaner and more cost-constrained, there is a growing demand for more advanced clinical trial analytics tools to better manage fragmented data.
In this webinar, the featured speakers will walk through four case studies and review all aspects of applying analytics to a study from operational and technical implementation to return on investment (ROI) and key performance indicators (KPIs) to measure success.
Register for this webinar to explore the evolution of clinical trial analytics and how they help predict clinical trial outcomes.
Join Rohit Nambisan, CEO & Co-Founder, Lokavant; and Bill Symonds, CEO, Enzyvant, for the live webinar on Tuesday, May 16, 2023, at 1pm EDT (10am PDT).
For more information, or to register for this event, visit Implementing Clinical Trial Analytics to Predict Trial Outcomes.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: vkovacevic@xtalks.com
Share article on social media or email: